These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729 [TBL] [Abstract][Full Text] [Related]
8. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease. Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539 [TBL] [Abstract][Full Text] [Related]
9. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881 [TBL] [Abstract][Full Text] [Related]
10. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384 [TBL] [Abstract][Full Text] [Related]
11. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Higuchi M Curr Alzheimer Res; 2009 Apr; 6(2):137-43. PubMed ID: 19355848 [TBL] [Abstract][Full Text] [Related]
17. Detection of brain amyloid β deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B. Kawai N; Kawanishi M; Kudomi N; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T Brain Inj; 2013; 27(9):1026-31. PubMed ID: 23662609 [TBL] [Abstract][Full Text] [Related]
18. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition. Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509 [TBL] [Abstract][Full Text] [Related]
19. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition. Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653 [TBL] [Abstract][Full Text] [Related]
20. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging. Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]